Drugs / Nepadutant
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00655083 | Mar 2008 → May 2009 | — | Menarini Group | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01532518 | Aug 2011 → Jul 2012 | — | Menarini Group | Completed | No outcome recorded |
| Phase 2 | NCT01309009 | Feb 2011 → Nov 2012 | infantile diarrhea | Menarini Group | Withdrawn | No outcome recorded |
| Phase 2 | NCT01258153 | Nov 2010 → Dec 2013 | — | Menarini Group | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nepadutant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01258153 ↗ |
| Action | Inhibit | “Neurokinin 2 receptor antagonist” CHEMBL1908318 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL1908318 ↗ |
| Route | Oral | “0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)” NCT00655083 ↗ |
| Target | TACR2 | “Neurokinin 2 receptor antagonist” CHEMBL1908318 ↗ |